AVRO | Jotup

AVROBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO

Retrieved on:

목요일, 5월 9, 2024

Class Action Lawsuit, Professional Services, Legal, Sale, KSF, AVRO

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points:

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AVROBIO, Inc. (NasdaqGS: AVRO) and Tectonic Therapeutic, Inc. pursuant to which pre-merger AVROBIO shareholders are expected to own approximately 22.3% of the combined company.
KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – SCTL, MDC, BATL, AVRO

Retrieved on:

금요일, 3월 1, 2024

Empire, Society, Sale, CDMO, MDC, Sekisui House, AVRO, Security (finance)

Under the terms of the agreement, SCTL shareholders are expected to receive $1.10 in cash per share they own.

Key Points:

Under the terms of the agreement, SCTL shareholders are expected to receive $1.10 in cash per share they own.
Under the terms of the agreement, MDC shareholders are expected to receive $63.00 in cash per share they own.
Under the terms of the agreement, AVRO shareholders are expected to own approximately 22.3% of the combined company.
Before you hire a law firm, you should talk to a lawyer and ask:
Do you recover money for shareholders?

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – AXNX, JNPR, BATL, AVRO

Retrieved on:

금요일, 2월 23, 2024

Empire, JNPR, Boston Scientific, Hewlett-Packard, Sale, AVRO, Security (finance)

Under the terms of the agreement, AXNX shareholders will receive $71.00 in cash per share they own.

Key Points:

Under the terms of the agreement, AXNX shareholders will receive $71.00 in cash per share they own.
Under the terms of the agreement, JNPR shareholders are expected to receive $40.00 in cash per share they own.
Under the terms of the agreement, AVRO shareholders are expected to own approximately 22.3% of the combined company.
Before you hire a law firm, you should talk to a lawyer and ask:
Do you recover money for shareholders?

AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO

Retrieved on:

수요일, 2월 14, 2024

Class Action Lawsuit, Professional Services, Legal, KSF, AVRO, Sale

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points:

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AVROBIO, Inc. (NasdaqGS: AVRO) and Tectonic Therapeutic, Inc. pursuant to which pre-merger AVROBIO shareholders are expected to own approximately 22.3% of the combined company.
KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

AVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AVROBIO, Inc. Is Fair to Shareholders

Retrieved on:

화요일, 1월 30, 2024

Legal, Professional Services, Fraud, AVRO, Advertising, Security (finance)

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AVROBIO, Inc. (NASDAQ: AVRO) and Tectonic Therapeutic, Inc. is fair to AVROBIO shareholders.

Key Points:

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AVROBIO, Inc. (NASDAQ: AVRO) and Tectonic Therapeutic, Inc. is fair to AVROBIO shareholders.
Upon completion of the proposed transaction, pre-merger AVROBIO shareholders are expected to own approximately 22.3% of the combined company.
On behalf of AVROBIO shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

AVROBIO and Tectonic Therapeutic Announce Merger

Retrieved on:

화요일, 1월 30, 2024

AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the “Merger”).

Key Points:

AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the “Merger”).
Under the terms of the agreement, AVROBIO will acquire 100% of the outstanding equity interests of Tectonic.
The private placement is expected to close in conjunction with the Merger in the second quarter of 2024.
“We are delighted to merge with AVROBIO at this important time for Tectonic.

The Vertical Flight Society Announces the Winners of the 40th Annual Student Design Competition

Retrieved on:

금요일, 8월 25, 2023

FAIRFAX, Va., Aug. 25, 2023 /PRNewswire/ -- The Vertical Flight Society (VFS) today announces the winners of its 40th Annual Student Design Competition. The team of University of Maryland took first place in the Graduate category and Georgia Institute of Technology/US Military Academy in the Undergraduate category. In addition, the Military Institute of Technology (Bangladesh) took Best New Undergraduate Entrant honors. Sikorsky, a Lockheed Martin Co., was the sponsor of this year's competition, supporting a total of $12,500 in prize money.

Key Points:

FAIRFAX, Va., Aug. 25, 2023 /PRNewswire/ -- The Vertical Flight Society (VFS) today announces the winners of its 40th Annual Student Design Competition.
Executive summaries for the top-winning entries from the 40th Student Design Competition are available at http://www.vtol.org/sdc , along with past winners.
The 40th (2022-2023) Student Design Competition was entitled, "High-Speed Vertical Takeoff and Landing (HSVTOL) Aircraft."
The Vertical Flight Society is the world's premier vertical flight technical society.

AVROBIO to Explore Strategic Alternatives

Retrieved on:

수요일, 7월 12, 2023

Research, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Disclosure, AVRO, Acquisition, DSM-IV codes, Pharmaceutical industry, Online shopping, Retail

AVROBIO has made the determination to halt further development of its programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.

Key Points:

AVROBIO has made the determination to halt further development of its programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.
As part of this evaluation process, AVROBIO will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, or other transaction.
There can be no assurance that its exploration will result in AVROBIO pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all.
AVROBIO has not set a timetable for completion of this evaluation process and does not intend to disclose further developments unless and until it is determined that further disclosure is appropriate or necessary.

AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million

Retrieved on:

월요일, 6월 12, 2023

Health, Biometrics, Stem Cells, Genetics, Other Health, Clinical Trials, Biotechnology, Wells Fargo, Gaucher, AVRO, HSC, Cystinosis, Glycogen storage disease type II, Hunter syndrome, TD, DSM-IV codes, Pharmaceutical industry, Novartis

(Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the closing of the previously announced agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for cystinosis to Novartis for $87.5 million in cash.

Key Points:

(Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the closing of the previously announced agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for cystinosis to Novartis for $87.5 million in cash.
AVROBIO retains full rights to its portfolio of first-in-class HSC gene therapies for Gaucher disease type 1 and type 3, Hunter syndrome and Pompe disease.
Proceeds from this transaction are expected to extend the Company’s cash runway into the fourth quarter of 2024.
TD Cowen and Wells Fargo Securities, LLC acted as financial advisors to AVROBIO in the transaction.

AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million

Retrieved on:

월요일, 5월 22, 2023

(Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced an agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash.

Key Points:

(Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced an agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash.
Pursuant to the terms of an asset purchase agreement, Novartis will pay AVROBIO $87.5 million in cash at closing, in consideration for the sale and transfer of certain assets related to the cystinosis program.
In addition, AVROBIO has exclusively licensed to Novartis certain other assets, know-how and other intellectual property related to AVROBIO’s gene therapy platform for use in cystinosis.
To support the transition of the program, AVROBIO also has agreed to provide under a separate agreement certain transition, knowledge transfer and other related services.